Search PubMedSearch

Biomedical subjects

J D Stephenson

Publications and source records attributed to J D Stephenson.

At least 19 recordsLinked to original sources

An AP-1-like motif in the first intron of human Pro alpha 1(I) collagen gene is a critical determinant of its transcriptional activity.

The first intron of the human Pro alpha 1(I) collagen gene contains an orientation-dependent enhancer composed of both positive and negative cis-acting elements involved in the transcriptional regulation of this gene. Deletion of a 360 bp Sau 3A intronic fragment spanning nucleotide +494 to +854 (S360) resulted in dramatic down-regulation of pCOL-KT (Thompson et al., J Biol Chem 266: 2549-2556, 1991). Using a DNaseI protection assay, we demonstrate a single footprint located at +590 to +615 in the S360 fragment; nuclear extracts prepared from mesenchymal and nonmesenchymal cells exhibited similar binding characteristics. A double stranded oligonucleotide representing a consensus Ap-1 binding sequence competed with S360 for binding. In contrast to what occurred in response to S360 deletion which was always accompanied by reduced expression, the deletion of the Ap-1 binding site (+598 to +off) caused either increased or decreased expression of the reporter gene depending on the target cell. Site-directed mutations in the Ap-1-like cis-element of Pro alpha 1(I) were also tested in transient expression assays. Consistent with the paradoxical results of Ap-1 deletion, we observed that the functional consequences of mutations in the Ap-1 site also varied in different cells. In A204 cells, one point mutation, which resulted in the loss of protein binding to S360, led to increased CAT activity while another point mutant, which retained binding of the Ap-1 like trans-acting factor(s), showed decreased CAT expression. The effects of these two mutations in the HFL-1 cells were exactly opposite of what was seen for A204 cells. Based on these observations, we postulate that the Ap-1 site plays a critical role in the transcriptional activity of the human Pro alpha 1(I) gene. The implications of an apparently dual mode of regulation through a single cis-regulatory element are discussed.

Base Sequence

Production of limbic motor seizures and brain damage by systemic and intracerebral injections of paraquat in rats.

The behavioural and neuropathological effects of both systemic and intrahippocampal injections of paraquat dichloride (1,1'-dimethyl 4,4'-bipyridinium dichloride) were studied in rats. Paraquat (0.1-1.0 mumol) injected into the dorsal hippocampus, produced limbic motor seizures within a few minutes of injection followed by neuronal damage in the CA1 and CA3 pyramidal cell layers, pyriform cortex, dentate granule cell layer and in the hilus fascia dentata at 24 hr (n = 9 rats). A smaller dose of paraquat (10 nmol) was ineffective. The effects of intrahippocampal injections of paraquat (1 mumol) were prevented by administering it together with atropine (50 nmol; n = 6 rats) or by giving it 60 min. after MK 801 (0.3 mg.kg-1 intraperitoneally). Systemic injections of paraquat (20-100 mg.kg-1) also produced forelimb clonus and rearing in 10 out of 15 animals. Neuronal cell death was found 24 hr later in 9 of these rats and was restricted to the pyriform cortex, the brain region with the highest concentrations of paraquat. Atropine (150 mg.kg-1 intraperitoneally given 60 min. previously) completely prevented the motor seizures but cell death still occurred in 2 of the 6 animals tested. In conclusion, both systemic and intrahippocampal injections of paraquat produced behavioural excitation accompanied 24 hr later by brain damage and antagonist studies suggested involvement of muscarinic and NMDA receptors in the neurotoxic mechanism.

Animals

Cholecystokinin octapeptide and caerulein injection into the dorsomedial nucleus accumbens potentiate apomorphine-induced jaw movements in rats.

The effects of bilateral intra-accumbal and intrastriatal injections of CCK-8 sulphate and its analogue, caerulein, on apomorphine-induced jaw movements were studied in ketamine-anaesthetized rats after C1 spinal transection. Jaw movements were detected by a photo-transducer attached to the mandible. CCK-8 (5, 10 and 20 ng) and its analogue, caerulein (1 and 5 ng), injected into the dorsomedial nucleus accumbens increased the frequency of apomorphine (0.2 mg/kg i.v.)-induced jaw movements. The potentiation was prevented by administration of a CCK-A receptor antagonist, lorglumide (5 ng), together with CCK-8 (20 ng) or caerulein (5 ng). Injection of lorglumide alone into the dorsomedial nucleus accumbens did not alter apomorphine (0.5 mg/kg i.v.)-induced jaw movements. Injections of CCK-8 (20 ng) and caerulein (5 ng) into adjacent sites (the ventrolateral nucleus accumbens, dorsal striatum and ventral striatum) did not affect the responses elicited by apomorphine (0.2 mg/kg i.v.). These results demonstrate that CCK-8 modulates responses elicited by a dopamine receptor agonist, apomorphine, in a region of the brain where CCK-8 is known to co-exist with dopamine.

Animals

Changes in motor activity and forebrain [propionyl-3H]propionylated-CCK-8 binding in mice after repeated administration of drugs affecting cholecystokinin receptors.

The effects of acute or repeated treatment of male albino BKW mice with caerulein, a cholecystokinin octapeptide (CCK-8) agonist, and with devazepide (MK-329) and L-365,260, antagonists at CCKA ('peripheral') and CCKB ('central') receptors respectively, on motor activity and [propionyl-3H]propionylated-CCK-8 ([3H]pCCK-8) binding were studied. Acute treatment with a large dose of caerulein (100 micrograms/kg s.c.) suppressed motor activity (line crossings and rearings) whereas devazepide (2 mg/kg i.p.) had the opposite action. L-365,260 (2 mg/kg i.p.) increased only the number of rearings. Tolerance developed to the locomotor effects of caerulein and devazepide when these same doses were administered once daily (caerulein) or twice daily (devazepide) for 10 days. Twice daily administration of L-365,260 (2 mg/kg) for 10 days did not significantly alter the locomotor activity of mice. The sedative effect of caerulein (20 micrograms/kg s.c.) was markedly reduced in mice receiving repeated injections of either a larger amount of caerulein (100 micrograms/kg) or devazepide but not after L-365,260. The stimulant effect of (+)-amphetamine (2 mg/kg s.c.) on motor activity was increased by subchronic administration of either devazepide or caerulein, but not by L-365,260. All three compounds (caerulein, devazepide and L-365,260) increased the number of [( 3H]pCCK-8 binding sites in mouse forebrain but the increase was only significant after L-365,260. The effects of long-term treatment with caerulein are probably related to the stimulation of CCKA receptors, whereas the paradoxically similar action of devazepide may be linked to the blockade of both subtypes of the CCK-8 receptor.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals

The effects of tianeptine on wet-dog shakes, fore-paw treading and a flexor reflex in rats are consistent with enhancement of 5-hydroxytryptamine uptake.

Tianeptine is a novel antidepressant which uniquely facilitates 5-hydroxytryptamine (5-HT) uptake. When given in a dose of 10 mg/kg to rats pretreated with either carbidopa or phenelzine, it markedly reduced the frequency of wet-dog shakes, fore-paw treading, tremor and hind-limb abduction evoked by L-5-hydroxytryptophan (L-5-HTP) given 30 or 60 min later. This effect of tianeptine was opposite to that of paroxetine, a selective 5-HT uptake inhibitor, which greatly increased the 5-HTP-induced behavioural syndrome. In contrast, tianeptine did not affect behaviours elicited by the 5-HT receptor agonists, 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) or (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI), which are not substrates for the 5-HT uptake process. In spinal animals, tianeptine attenuated an ipsilateral flexor reflex, an effect opposite to that of citalopram, a selective 5-HT uptake inhibitor. These effects of tianeptine are consistent with its ability to increase 5-HT reuptake.

Amphetamines

The effect of chronic ritanserin and clorgyline administration on 5-HT2 receptor linked inositol phospholipid hydrolysis.

We have previously shown that chronic administration of the 5-hydroxytryptamine (5-HT) receptor antagonist, ritanserin (10 mg/kg/day) or the monoamine oxidase type A inhibitor (MAOI), clorgyline (2 mg/kg/day), results in a reduction in 5-HT2 receptor number in rat cerebral cortex. This study investigates the effects of acute and chronic ritanserin administration, on 5-HT2 receptor linked inositol phospholipid hydrolysis in rat cortical slices and compares it with the effect of a chronic clorgyline regimen. [3H]Myo-inositol (50 microCi) was used to label inositol phospholipids. Their subsequent hydrolysis in the presence or absence of 5-HT was determined by the accumulation of [3H]myoinositol monophosphate ([3H]InsP). Addition of 5 nM ritanserin to slices had no effect on basal or 5-HT stimulated [3H]InsP accumulation whereas 100 nM ritanserin blocked the stimulated response by 65%. Acutely, ritanserin (15 mg/kg i.p.) completely blocked 5-HT stimulated [3H]InsP accumulation. Chronic ritanserin or clorgyline treatment had no effect on basal levels of [3H]InsP accumulation compared to controls (mean value 3125 +/- 298 dpm/mg protein). Ritanserin increased 5-HT stimulated [3H]InsP accumulation at 1 microM, 100 microM and 1 mM 5-HT and this effect was significant at 100 microM 5-HT. Clorgyline had no significant or consistent effect on 5-HT stimulated [3H]InsP accumulation at 1 microM, 100 microM and 1 mM 5-HT. Thus the effects of both chronic clorgyline and ritanserin administration on 5-HT2 linked inositol phospholipid hydrolysis do not correlate with their effects on 5-HT2 receptor number (Bmax). The situation is further complicated since ritanserin significantly increases phosphatidylinositol (PtdIns), phosphatidylinositol 4-phosphate (PtdIns4P) and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) labelling whereas clorgyline significantly increases PtdIns and PtdIns4P labelling. The implications of this are discussed.

Animals

Further evidence for an anomalous regulation of cortical 5-HT2 receptors: studies with 5-HT precursors.

Rats pretreated with either phenelzine (50 mg/kg 18 h and 12 mg/kg 90 min previously) or carbidopa (25 mg/kg 30 min previously) then given tryptophan or 5-hydroxytryptophan (5-HTP), developed wet-dog shakes which were more intense after 5-HTP. Cortical 5-HT2 receptors were significantly reduced within 3 h of tryptophan (150 or 500 mg/kg) given to phenelzine-treated rats. 5-HTP either did not affect (150 mg/kg) or slightly increased (350 mg/kg) 5-HT2 receptor numbers in rats pretreated with carbidopa. The response to 5-HTP (350 mg/kg) was not altered by pretreatment with alpha-methyl-p-tyrosine, haloperidol, propranolol or yohimbine.

5-Hydroxytryptophan

Production of wet-dog shakes in rats and down-regulation of spinal 5-HT2 receptors.

5-HT2 receptors, labelled with [3H]ketanserin, were shown to occur in a low concentration in the spinal cord of rats. The receptor numbers were reduced by 37% within 3 h of giving paroxetine to phenelzine-treated rats and remained low for at least 24 h. Paroxetine also evoked wet-dog shakes. These were of similar frequency in spinal (Cl transection) and intact rats and lessened within 3 h, perhaps because of receptor down-regulation.

Animals

Effects of intrastriatal injections of selective dopamine D-1 and D-2 agonists and antagonists on jaw movements of rats.

The effects of bilateral intrastriatal injections of the selective D-1 and D-2 antagonists, SCH23390 and sulpiride on apomorphine-induced jaw movements were studied in ketamine-anaesthetized rats after C1 spinal transection. A photo-transducer attached to the lower mandible automatically detected jaw movements. Apomorphine (0.2, 0.5 and 1.0 mg/kg i.v.) dose dependently increased jaw movements, an effect prevented by prior administration into the ventral striatum of either SCH23390 (0.1, 0.5 and 1 microgram) or sulpiride (125 ng). To be effective, SCH23390 had to be given less than 30 min before apomorphine whereas sulpiride had to be given earlier. Sulpiride injected into the dorsal striatum potentiated the effects of apomorphine, an action prevented by administering the sulpiride with SCH23390. Local application of the selective D-1 and D-2 agonists, SKF38393 (5 micrograms) and quinpirole (10 micrograms) into sites within the ventral striatum from which repeated jaw movements could be obtained by electrical stimulation, also evoked jaw movements; the effects of combining the two drugs were much greater than the effects of either drug alone.

Animals

Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

In marmosets, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes degeneration of the cell bodies of the substantia nigra and the animals subsequently develop parkinsonian symptoms. Cystometrograms obtained from such animals while under pentobarbitone anaesthesia, showed their bladders to be hyperreflexic when compared to those of normal animals of the same age (less than 2 years). Bladder hyperreflexia is present in many parkinsonian patients and is difficult to treat, partly because it is made worse by dopaminergic agents. This is the first demonstration of an effect of MPTP on this type of peripheral function. It suggests the suitability of MPTP-treated marmosets for studying the mechanisms by which a loss of nigrostriatal dopamine leads to bladder hyperreflexia and for devising pharmacological strategies which may be of therapeutic value in the clinic.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Gastric control of food intake.

Inhibition of gastric emptying leads to enhanced satiety and this mechanism may contribute to the undereating observed after administration of cholecystokinin (CCK) and fenfluramine, and in patients with anorexia nervosa. Pyloric smooth muscle bears specific CCK receptors and the evidence suggests that a major site of action for CCK satiety is in the periphery. CCK receptors are widespread in the neonatal rat stomach but not in the brain and over the first two weeks of life binding in the stomach decreases and that in the brain increases. This and the finding that independent ingestion as well as gastric emptying are inhibited by CCK at birth suggest the stomach as its likely site of action in the neonatal rat. Fenfluramine inhibits feeding in animals and in patients with bulimia nervosa. In monkeys, fenfluramine inhibits gastric emptying and this action correlates with its feeding inhibition. Patients with anorexia nervosa who are acutely starving and rats maintained on a restricted diet have delayed gastric emptying. Anorexic patients showed abnormal reporting of both hunger and satiety, and, together with those with bulimia nervosa, often associated gastric contents with symptoms of eating disorder, indicating disturbed interpretation of gastric signals.

Animals

Purification of the human alveolar macrophage mannose receptor.

We report here the first isolation of a mannose receptor from human lung, and identify the alveolar macrophage as the cell of origin. The receptor was purified from detergent-solubilized lung tissue by absorption to mannose- and fucose-Sepharose, and elution with EDTA. The eluted protein had a molecular weight of 175 kD. Maximum binding of 125I-mannan-2 to the isolated receptor occurred at pH 7.5. Binding was inhibited by 40 micrograms/ml mannan (75%); 200 mM mannose (89%); and 200 mM fucose (93%). Galactose (200 mM) had no effect. Polyclonal antibodies raised against the purified receptor reacted with the purified 175 kD protein and a 175 kD protein from detergent extracts of human alveolar macrophages by immunoblot analysis. The antibody immunoprecipitated a 175 kD protein from solubilized 125I-labeled human alveolar macrophage membranes. These studies indicate that the 175 kD protein purified from human lung is the cell surface alveolar macrophage mannose receptor.

Binding, Competitive

Classification of opioid and 5-hydroxytryptamine receptors by means of discriminative drug effects.

Behavioural studies can help to validate, modify and refine schemes for classifying receptors that are developed from electrophysiological and biochemical experiments. Drug discrimination constitutes one family of behavioural techniques that is being extensively used for studying subtypes of receptors, mainly because the methods often have remarkably high pharmacological specificity but can be applied to agents from a diverse range of classes. This article reviews briefly studies on agents acting through opioid and 5-hydroxytryptamine systems, where the results of the behavioural studies are very largely consistent with findings from other approaches. Many drugs used in such work have limited selectivity for putative subtypes of receptor, but little is known about how such compound pharmacological stimuli are processed in drug discrimination experiments. The characteristics of the discriminative stimuli produced by a mixture of drugs are discussed with respect to implications for effects of single drugs with multiple actions. Based on these initial experiments on discrimination of a mixture of nicotine and midazolam, it appears that the components of a compound pharmacological stimulus may be perceived and processed independently.

8-Hydroxy-2-(di-n-propylamino)tetralin

A putative non-cholinergic mechanism in urinary bladders of New but not Old World primates.

The effects of atropine on bladder contractions evoked by sacral ventral root stimulation were investigated in two species of New World monkey (marmoset and cebus) and in paraplegic man. The findings were then compared to those previously obtained for the cat and two species of Old World monkey (rhesus and baboon). The results show the marmoset and cebus to represent a transitional stage between the complete sensitivity of the bladders of Old World monkeys to atropine and the relative insensitivity of the cat bladder. The bladder response is shown to comprise two components, an atropine sensitive component which is slow in onset and an atropine resistant component which is easily fatigued. The experiments in paraplegic people confirm that the parasympathetic innervation of the bladder of man is, like that of Old World monkeys, exclusively cholinergic. A behavioural interpretation is tentatively offered to explain the two types of innervation.

Animals

Effects of antidepressant drug combinations on cortical 5-HT2 receptors and wet-dog shakes in rats.

Rats pretreated with the monoamine oxidase inhibitor, phenelzine 18 h (46.8 mg/kg) and 90 min (11.7 mg/kg) previously or only 90 min (46.8 mg/kg) previously developed a 5-HT dependent syndrome (including wet-dog shakes, WDS) when given the 5-HT uptake inhibitor, paroxetine (11.6 mg/kg). After 2 h, but only in rats pretreated with 2 injections of phenelzine, there was a gradual reduction in the number of cortical 5-HT2 receptors, determined in vitro with [3H]ketanserin, and this was temporally related to a reduction in the frequency of WDS. Both effects (down-regulation and WDS) were prevented by the 5-HT2 receptor antagonist, pirenperone. A second injection of paroxetine at 3 h evoked additional WDS in rats pretreated with 1 injection of phenelzine but not in rats pretreated with 2 injections, suggesting that spinal 5-HT2 receptors might also have been down-regulated at the same time. Similar results were obtained when rats were pretreated instead with the selective MAO A inhibitor, clorgyline or when given either citalopram or fenfluramine instead of paroxetine. 5-HTP also evoked WDS in phenelzine-treated rats and markedly increased brain 5-HT concentration but only slowly down-regulated 5-HT2 receptors; in carbidopa-treated animals, 5-HTP was without effect on receptor numbers despite production of frequent WDS. It thus appears that drugs which increase synaptic 5-HT (as indicated by production of WDS) by interference with the release or reuptake of 5-HT more readily down-regulate 5-HT2 receptors than 5-HTP which does not directly affect these mechanisms.

5-Hydroxytryptophan